A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: a phase II trial
- 173 Downloads
Background and aim
The aim of this study was to investigate the possible effect of a COX-2 inhibitor in addition to chemoradiation of locally advanced rectal cancer.
Materials and methods
The study included 35 patients with rectal adenocarcinoma. All patients had a tumor localised ≤10 cm from the anal verge and a circumferential margin ≤5 mm on a magnetic resonance scan. The patients were scheduled to receive external radiation with a tumor dose of 60 Gy supplemented with an endorectal boost of 5 Gy. Concurrent with radiation, the patients received uracil-tegafur 300 mg/m2 daily. Celexocib was scheduled throughout the radiation period in a dose of 400 mg × 2 daily.
A macular papular rash was seen in 17 (49%) of the patients leading to stop of medication with celecoxib. Thirty-three patients were operated, and all patients responded to treatment. Complete pathological remission was found in 21% of the patients and further 24% had only microscopic residual tumor cells. The results did not suggest any difference according to the accomplishment of the COX-2 medication.
The addition of a COX-2 inhibitor to chemotherapy-enhanced radiation treatment of rectal cancer was not feasible due to a high incidence of rash in the present study.
KeywordsRectal cancer COX-2 inhibitor Chemoradiation
Conflict of interest statement
We declare that no actual or potential conflict of interest exists.
- 3.Roh MS, Colangelo L, Wieand HS, et al (2004) Response to preoperative multimodality therapy predicts survival in patients with carcinoma of the rectum. Abstract 3505, ASCO 2004 annual MeetingGoogle Scholar
- 5.Conroy T, Bonnetain O, Chapet O, et al (2004) Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3, 4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial. ASCO Abstract 3626, (American Society of Clinical Oncology) ConferenceGoogle Scholar
- 6.Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2004) Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 72:15–24PubMedCrossRefGoogle Scholar
- 13.Leese PT, Hubbard RD, Karim A, et al (2000) Effects of Celecoxib, a novel cyclooxygenasec2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 40(2):124–132Google Scholar
- 15.Liao ZX (2003) A phase I study combining thoracic radiation (RT) with celecoxib in patients with non-small cell lung cancer (NSCLC). Abstract 867, ASCO Annual MeetingGoogle Scholar